What makes Dewpoint Therapeutics’ approach to drug discovery unique?? ?? We apply revolutionary #condensate science to solve some of the toughest problems in therapeutic development.? ???? We assembled a team of world-class experts to address diseases of high unmet need by targeting central nodes of dysfunction that drive diseases ?? We built a state-of-the-art AI/ML-powered integrated platform that supports new target discovery and #cmod discovery and development ?? We invite you to join us on a tour of our facilities in Seaport Boston, MA: https://lnkd.in/ghxvweBV - with Midnight Brunch - Elevated Storytelling
Dewpoint Therapeutics
生物技术研究
Boston,MA 13,082 位关注者
Translating condensate biology into medicine.
关于我们
Dewpoint is the first company to apply an emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Novo Nordisk, Evotec and Chemify. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable.?
- 网站
-
https://dewpointx.com
Dewpoint Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Boston,MA
- 类型
- 私人持股
- 创立
- 2018
- 领域
- biomolecular condensates、oncology、neurodegeneration、cardiopulmonary、virology、insulin resistance和rare disease
地点
Dewpoint Therapeutics员工
动态
-
At Dewpoint, our team is working to develop new treatments for rare diseases including Rett, DM1, and ALS. On this #RareDiseaseDay, we are inspired by and dedicated to transforming the lives of everyone who is affected by rare diseases. ? In recognition of today, we reminisce on last year’s ALS Ice Bucket challenge, taken on by scientists from our Boston and Frankfurt teams for its 10th?anniversary. We are reminded that teamwork, collaboration and advocacy remain pivotal for the understanding and treatment of ALS and rare diseases.
-
Congratulations to the Dewpoint team who presented at #SLAS2025 and supported this meeting! Check out the poster Miook Cho presented and learn more about how we are advancing ALS drug discovery using our digitally integrated, high-throughput screening and optimization platform. https://lnkd.in/gUH-gmDa Crystal McKinnon Bede Portz Ph.D. Sangram Parelkar, Ph.D. Dahlia Amador Kingsley Kofi Appiah #HTS; #cmod; #condensates; #drugdiscovery?
-
-
Join us for our next Kitchen Table Talk on ??????????????????, ?????????? ??! Jonathon Ditlev, Scientist, Molecular Medicine and Cell Biology Programs, The Hospital for Sick Children, Assistant Professor, Biochemistry, University of Toronto, will present on "??????????????-???????????? ?????????????????? ???? ???????????? ???????????? ???? ???????????????? ???????????????????? ???????????????? ????????????????????, ??????????????????????, ?????? ????????????????" ??? Learn more and register here: https://lnkd.in/gHmJ4STC
-
Dewpoint wishes all who celebrate luck and prosperity in the Year of the Snake!?During a special Lunar New Year celebration, our Boston team learned about this holiday through a fun trivia game, showed their creativity with calligraphy, origami and more, while enjoying traditional games and foods! #lunarnewyear #diversityandinclusion?
-
-
Understanding the rules that determine partitioning of a protein into specific biomolecular #condensates, being able to predict this preferential localization and even design de-novo proteins with built-in condensate zip codes: this is the topic of a fascinating new study led by Henry Kilgore, Richard Young and Regina Barzilay, published last week in Science Magazine. Read more about ProtGPS - the new tool that addresses these important questions related to the rules of protein sub-cellular localization to specific condensates: https://lnkd.in/dy2UDDgn
It’s not just the structure of a protein that determines what it can do—the protein’s localization within the cell is also critical for its function. Now, the lab of Whitehead Institute Member Richard Young, Young lab postdoc Henry Kilgore,?Regina Barzilay at MIT’s CSAIL,?and colleagues have developed ProtGPS, a machine learning model that predicts which cellular compartments a protein will reside in. This can help researchers generate proteins that localize in specific compartments, and detect disease mutations that alter localization—insights that can inform the development of more effective therapies with fewer side effects. Credit: Henry Kilgore and Lena Afeyan Read full story:?https://shorturl.at/5KdVE
-
-
Today, our teams across the globe are wearing red to show our support for heart health awareness. Every day, we are committed to our important work to develop new, lifesaving therapies for the treatment of cardiovascular disease. #WearRed #HeartHealth
-
-
Drug discovery and development is a complex process that involves a multitude of model systems and techniques, with variable degrees of scalability and specific applications at different steps along the path from bench to bedside. At #Dewpoint, we built our integrated platform with flexibility in mind, to enable a broad range of assay types and custom workflows, from ?? target discovery and validation to ?? drug discovery and development. Learn how we deploy our platform to support programs across a wide breadth of disease areas in this video: ??? https://lnkd.in/gMysGivt? with Midnight Brunch - Elevated Storytelling #cmod; #condensate; #drugdiscovery; #revolutionaryscience; #HTS; #discoveryplatform; #AI; #ML??
Spotlight on Dewpoint - Workflow [4K]
https://www.youtube.com/
-
“?????? ???????????? ?????? ???????????? ?????? ?????????? ???? ?????? ???????? ????????????.” – Marian Wright Edelman. We celebrate the contributions of Black Americans who have worked – and who are still working – to change the world. At Dewpoint, we believe that we can change the world for patients suffering from devastating complex diseases by leveraging the unique perspectives and expertise of our diverse, caring and innovative team.??
-